Trial Profile
A Phase 2 Pilot, Multicenter, Single Arm Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GSK1070806 Plus Standard of Care for the Prevention of Delayed Graft Function in Adult Subjects After Renal Transplantation
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs GSK 1070806 (Primary)
- Indications Delayed graft function
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 10 Apr 2022 This trial has been completed in Spain (Global end date: 06-03-2008), according to European Clinical Trials Database record.
- 05 Apr 2017 Planned End Date changed from 25 May 2018 to 23 Nov 2018.
- 05 Apr 2017 Planned primary completion date changed from 2 Jun 2017 to 1 Dec 2017.